Why we evaluate
External evaluations are an essential component of our approach to grant management and monitoring, transparency and accountability, and communicating impact and learning.
External evaluations are one of several approaches that we apply to ensure effective grant performance to deliver global health impact. Other approaches include regular internal monitoring, external audits, partner engagement, and external verifications. External evaluations provide us with an independent assessment of the results delivered through our grants, input for course correction and a consolidation of lessons learned and recommendations to inform future investments.
How we approach evaluation
Unitaid requires at least one evaluation over the course of each grant. We typically commission external end-of-grant evaluations within 12 months before or after grant closure. Mid-term evaluations are optional and may be substituted with other available assurance mechanisms.
External evaluations are contracted, funded and managed by Unitaid. We select evaluators through an open, competitive procurement process that follows best practice, with clear terms of reference outlining required experience and expertise. To promote efficient use of resources, we prioritize selection of evaluators with a presence in the region/countries of implementation and ensure evaluators make use of existing data, research and findings of previously completed evaluations.
Our evaluation framework
Our approach to evaluation is guided by our evaluation framework. This framework is based on the internationally accepted evaluation framework of the Organisation for Economic Co-operation and Development (OECD) Development Assistance Committee (DAC), including its principles and criteria for grant evaluations.
The evaluation framework is further aligned with our strategy.
We use this framework as the basis to develop the terms of reference that outlines the purpose and scope of work for a specific evaluation. Evaluation questions are prioritized and tailored according to the focus of the project or group of projects under evaluation and the information needs. Appropriate data sources and methods are then defined to respond to each evaluation question.
Unitaid’s evaluation framework and additional guidance for implementers and evaluators is available here.
How we share and use evaluation findings
We disseminate evaluation findings and learning widely among our stakeholders and partners. Final reports are posted on our website (see below).
The results of end-of-grant evaluations are used to inform annual reporting on our strategic key performance indicators (KPIs) and to help estimate our impact. Evaluation recommendations are used to support the ongoing performance management of our active portfolio and to inform the design of future investments.
- External review of Unitaid’s 2017-2021 strategy
- End-of-grant evaluation of Medicine Patent Pool (MPP) 2016-2020 grant
Recently completed evaluations:
- HIV Molecular diagnostics joint evaluation, Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), Clinton Health Access Initiative (CHAI), and UNICEF, Joint Portfolio Level End-of-Project Evaluation, July 2021
- Unitaid investments in Hepatitis C, Foundation for Innovative New Diagnostics (FIND) and Coalition PLUS, Joint Portfolio Level Evaluation and End-of-Project Evaluations, June 2021
- HIV Self-Testing AfRica (STAR) Initiative, Population Services International (PSI) & Society for Family Health (SFH) – South Africa, Phase 2, End-of-Project Evaluation, May 2021
- Evaluation of CHAI Community access to rectal artesunate for malaria (CARAMAL) and Medicines for Malaria Venture (MMV) Supply Side Grant, May 2021
- Investing in insecticides to fight malaria (NgenIRS project), Innovative Vector Control Consortium, End-of-Project Evaluation, September 2020
- Providing access to viral-load monitoring and early-infant diagnosis by SAMBA, Diagnostics for the Real World, End-of-Project Evaluation, November 2019
- Better HIV treatment for infants and young children, Drugs for Neglected Diseases Initiative (DNDi), End-of-Project Evaluation, April 2019
- Improving access to diagnosis and treatment for hepatitis C in low- and middle-income countries, Médecins Sans Frontières, End-of-Project Evaluation, February 2019
- Generating demand for hepatitis C treatment, Coalition PLUS, Mid-term evaluation, October 2018
- Innovation in paediatric market access (IPMA), Clinton Health Access Initiative (CHAI), End-of-Project Evaluation, November 2018
- Sustainable quality control of rapid diagnostic tests for malaria, Foundation for Innovative New Diagnostics (FIND), End-of-Project Evaluation, June 2018
- Expanding HIV self-testing in Africa (Star Phase 1), Population Services International (PSI), Mid-term Evaluation, March 2018
- TBXpert: Innovative diagnostics for multidrug-resistant tuberculosis (MDR-TB), Global TB Programme, End-of-Project Evaluation, July 2017
- Seasonal malaria chemoprevention for children in the Sahel (ACCESS-SMC), Malaria Consortium, Mid-term Evaluation, July 2017
- Addressing neglected childhood tuberculosis (STEP-TB), TB Alliance, End-of-Project Evaluation, July 2017
- Better treatment for severe malaria, Medicines for Malaria Venture (MMV), End-of-Project Evaluation, March 2017
- WHO prequalification for diagnostics and medicines, World Health Organization (WHO), Mid-term Evaluation, June 2016
- Click here to find older evaluations